Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Status:
Recruiting
Trial end date:
2037-11-10
Target enrollment:
Participant gender:
Summary
This phase I trial evaluates the side effects and best dose of mesothelin-specific T-cells
(FH-TCR-Tᴍsʟɴ) in treating patients with pancreatic ductal adenocarcinoma that has spread to
other places in the body (metastatic). Chemotherapy drugs, such as cyclophosphamide and
fludarabine, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading, and may help
increase the efficacy from the infused T cells. FH-TCR-Tᴍsʟɴ is an autologous T cell therapy
targeting mesothelin, an antigen overexpressed by pancreatic cancer cells. T cells are
infection fighting blood cells that can kill tumor cells. The T cells given in this study
will come from the patient and will have a new gene put in them that makes them able to
recognize mesothelin, a protein on the surface and inside tumor cells. These
mesothelin-specific T cells may help the body's immune system identify and kill mesothelin+
tumor cells. Giving chemotherapy with FH-TCR-Tᴍsʟɴ may kill more tumor cells in the treatment
of patients with metastatic pancreatic ductal adenocarcinoma.